Tesamorelin and Visceral Fat: What the Clinical Research Shows

What tesamorelin is and how it works

Tesamorelin is a 44-amino-acid synthetic peptide derived from the naturally occurring growth hormone-releasing hormone, with a trans-3-hexenoic acid group attached to the N-terminus. That modification does not change the binding properties at the pituitary GHRH receptor, but it substantially slows the rate at which the peptide is degraded by circulating dipeptidyl peptidase IV. Native GHRH has a plasma half-life measured in minutes; the chemical modification gives tesamorelin a longer effective window of activity.

The mechanism follows the normal GH axis pathway. Tesamorelin binds pituitary GHRH receptors and stimulates pulsatile release of growth hormone. That released GH then acts on target tissues directly and also drives hepatic production of IGF-1. In adipose tissue, GH signaling promotes lipolysis, the breakdown of stored triglycerides, while suppressing lipogenesis. Visceral adipose tissue is particularly sensitive to GH-mediated lipolytic signaling, which is why GHRH analogs can selectively reduce visceral fat without producing the same degree of change in subcutaneous depots.

The FDA-approved indication and the Egrifta trials

HIV-associated lipodystrophy is a syndrome involving abnormal fat redistribution that can occur in people living with HIV, particularly those on antiretroviral therapy. It is characterized by excess visceral and central fat accumulation alongside peripheral fat loss and carries metabolic consequences including insulin resistance and dyslipidemia. Before tesamorelin, there was no approved pharmacological treatment targeting the visceral component.

The pivotal clinical trials supporting the FDA approval were two randomized, double-blind, placebo-controlled trials. Falutz and colleagues published phase 3 data in the New England Journal of Medicine in 2010 reporting the results of a 26-week trial in HIV-infected patients with abdominal obesity. Participants received tesamorelin 2 mg subcutaneously once daily or placebo. Visceral adipose tissue, measured by CT imaging, decreased significantly in the tesamorelin group compared with placebo. The treatment difference was approximately 18 percent reduction in visceral fat area. Secondary measures including IGF-1 levels and patient-reported abdominal appearance also favored tesamorelin.

A second phase 3 trial published in The Lancet HIV in 2010 examined whether patients who responded to tesamorelin at 26 weeks and then continued treatment maintained their reduction compared to those switched to placebo. Patients who continued active treatment maintained their visceral fat reduction through 52 weeks. Patients switched to placebo regained a substantial portion of the fat they had lost, indicating that the effect is treatment-dependent rather than permanent.

• •FDA approved tesamorelin (Egrifta, Theratechnologies) in November 2010 for HIV lipodystrophy-associated visceral fat reduction
• •Approval was based on CT-measured visceral fat reduction as the primary endpoint, a clinically accepted imaging outcome
• •The visceral fat reduction seen at 26 weeks was not permanent; discontinuation resulted in substantial fat regain within months
• •IGF-1 levels rose during treatment and returned toward baseline after discontinuation
• •Tesamorelin did not produce weight loss in the classical sense; it redistributed composition rather than reducing total body mass

Research in populations without HIV lipodystrophy

Following the HIV lipodystrophy approval, researchers examined whether tesamorelin's visceral fat effects would extend to other populations with excess central adiposity. The general obesity and age-related visceral fat questions are commercially and scientifically relevant because visceral fat accumulation is a component of metabolic syndrome, insulin resistance, and cardiovascular risk in the broader population, not only in HIV-infected patients.

A trial published in Diabetes Care by Stanley and colleagues in 2012 evaluated tesamorelin in non-HIV individuals with abdominal obesity. The trial reported significant reductions in visceral fat in the tesamorelin group compared with placebo over 26 weeks, with an effect size directionally similar to what was seen in the HIV trials. IGF-1 also rose significantly. The trial was not powered for cardiovascular or diabetes outcomes; it focused on the fat composition endpoint. This study is frequently cited as evidence that the visceral fat effect generalizes beyond the HIV lipodystrophy context, though it remains a single trial in a relatively small sample.

Older adults with abdominal obesity represent another studied population. Age-related GH decline, sometimes called somatopause, is associated with increasing visceral fat accumulation, and GHRH analogs have been proposed as a way to partly restore GH pulsatility and its metabolic effects. Published trial data in this population shows tesamorelin can raise GH and IGF-1 and produce visceral fat reduction, though long-term data and clinical outcome data remain limited.

Cognitive function research

A separate line of tesamorelin research has examined potential effects on cognitive function, motivated by evidence that GH and IGF-1 play roles in brain metabolism and that GH-deficient adults show cognitive impairment that can improve with GH replacement. Some researchers have investigated whether stimulating GH release with tesamorelin might have cognitive benefits in older populations at risk for decline.

Baker and colleagues at the University of Wisconsin published a randomized controlled trial in JAMA Neurology in 2021 examining tesamorelin in older adults with mild cognitive impairment or normal aging. The trial reported that tesamorelin improved performance on a verbal learning and memory task compared with placebo over a 20-week period. IGF-1 levels were raised by treatment and the cognitive effect was correlated with IGF-1 change in the tesamorelin group. This is a single trial with a specific outcome measure, not a comprehensive demonstration of dementia prevention, and the authors called for replication and longer follow-up.

Effects on lipids, liver, and metabolic markers

Beyond visceral fat, published tesamorelin trials have measured secondary metabolic outcomes with mixed results. Triglyceride levels showed significant reductions versus placebo in the HIV lipodystrophy trials, which is consistent with the lipolytic mechanism and reduced hepatic lipid delivery from visceral fat. This effect was clinically meaningful in a population where lipodystrophy-associated dyslipidemia carries cardiovascular risk.

Liver fat is a downstream consequence of visceral fat and ectopic lipid deposition, and tesamorelin has been studied in non-alcoholic fatty liver disease in HIV-infected patients. A randomized controlled trial published in The Lancet HIV in 2019 by Falutz and colleagues reported that tesamorelin reduced liver fat content measured by MRS in HIV-infected adults with NAFLD. This adds to the mechanistic picture: reducing visceral fat and improving the metabolic environment around the liver appears to translate into measurable changes in hepatic fat.

Safety profile from published trials

The tesamorelin safety profile is well characterized relative to most investigational peptides because it completed a full phase 3 clinical development program. The most commonly reported adverse effects across trials were injection site reactions, fluid retention (peripheral edema and arthralgia reflecting GH-mediated water handling), and musculoskeletal discomfort. These are consistent with the known biology of GH axis stimulation.

The glucose metabolism effect warrants particular attention. GH raises blood glucose by opposing insulin-stimulated glucose uptake in muscle and adipose tissue. In the HIV trials, some participants showed increases in fasting glucose and HbA1c. The clinical program excluded patients with uncontrolled diabetes, and monitoring of glucose parameters was part of the trial protocols. For individuals with existing insulin resistance or prediabetes, GH axis stimulation carries a trade-off between visceral fat reduction benefits and potential glucose handling effects.

• •Injection site reactions are the most commonly reported local adverse effect
• •Fluid retention, peripheral edema, and joint discomfort are consistent on-mechanism effects seen across GH-stimulating compounds
• •Glucose metabolism changes, including small fasting glucose increases, have been reported and require monitoring in at-risk individuals
• •Tesamorelin is contraindicated in active malignancy because IGF-1 has proliferative effects on some tumor types
• •Tesamorelin is contraindicated in pregnancy and in patients with disruption of the hypothalamic-pituitary axis from prior surgery or radiation
• •No long-term safety data beyond 52 weeks from controlled trials is available from the approved indication program

Regulatory status and research context

Tesamorelin was approved by the FDA in November 2010 under the brand name Egrifta (subsequently reformulated as Egrifta SV). Health Canada approved it for the same indication in Canada. The approved indication is narrow and specific: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is not approved for general obesity, age-related body composition changes, cognitive enhancement, or performance purposes.

Outside its approved HIV lipodystrophy indication, tesamorelin is available from compounding pharmacies in some jurisdictions under physician supervision, and it is also available from research chemical suppliers as a research-grade peptide. Material obtained outside a licensed pharmacy does not carry the quality controls and purity standards of the approved pharmaceutical product. This distinction matters for research purposes.

The World Anti-Doping Agency prohibits growth hormone-releasing factors, a category that explicitly covers GHRH analogs including tesamorelin, under section S2 of its Prohibited List at all times. The prohibition applies regardless of therapeutic intent. Athletes subject to WADA rules who use tesamorelin face anti-doping consequences.

Compound reference pages